Shield Therapeutics

25 articles about Shield Therapeutics

• Shield Therapeutics PLC (“Shield”) to Webcast Live at Life Sciences Investor Forum June 24th

  6/21/2021

  Shield Therapeutics PLC today announced that Greg Madison, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on June 24 th . DATE: Thursday, June 24 th TIME: 10.00 am ET

• Shield Therapeutics plc - Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru®

  1/29/2019

  Shield Therapeutics plc (LSE: STX) a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru®, a novel oral ferric iron therapy that is approved and marketed in the European Union for the treatment of iron deficiency (ID) in adults and in Switzerland for the treatment of iron deficiency anaemia (IDA) in adults with inflammatory bowel disease

• Shield Therapeutics plc: Business and trading update

  1/24/2019

  Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today provides a business and unaudited trading update for the year ended 31 December 2018.

• Shield Therapeutics plc: Appointment of Chairman

  1/23/2019

  Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of James Karis as non-executive Chairman of the Company with immediate effect.

• Shield Therapeutics announces the US New Drug Application PDUFA date for Feraccru®

  12/13/2018

  Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today announces that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of Feraccru®

• Shield Therapeutics notes UK launch of Feraccru® by Norgine

  12/5/2018

  Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the announcement today by Norgine that they have launchedFeraccru® in the UK. 

• Shield Therapeutics announces the New Drug Application for Feraccru® has been accepted for filing and review by the FDA

  12/3/2018

   Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today announces that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Feraccru®, Shield’s lead product.

• Shield Therapeutics Completion Of Patient Enrollment In Pivotal AEGIS-CKD Phase III Study

  10/10/2017

• Shield Therapeutics U.S. Composition Of Matter Patent

  9/6/2017

• Shield Therapeutics Board Change

  11/7/2016

• Shield Therapeutics Release: Composition Of Matter Patent Granted On Feraccru

  9/7/2016

• In Need of Cash, UK's Shield Therapeutics Could Consider Partnerships with Amgen or Johnson & Johnson

  2/16/2016

• Shield Therapeutics Postpones IPO Due to Unfavourable Market Conditions

  10/5/2015

• Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal

  1/9/2015

• Shield Therapeutics Announces The Acceptance For Review By The European Medicines Agency Of The Marketing Authorisation Application For Feraccru®

  1/7/2015

• Shield Therapeutics Announces Acceptance Of ST10 Abstract For Presentation At ECCO Congress 2014

  2/4/2014

• Shield Therapeutics' ST10 Delivers Robust Results Meeting Both Primary And Secondary Endpoints In The Pivotal AEGIS Phase 3 Program For The Treatment Of Iron Deficiency Anemia In Inflammatory Bowel Disease

  1/7/2014

• Shield Therapeutics Release: FDA Grants Approval Of IND To Commence A Phase 3 Pivotal Study For ST10 For The Treatment Of Iron Deficiency Anemia In Chronic Kidney Disease

  12/16/2013

• Shield Therapeutics Files Investigational New Drug Application For ST10 For The Treatment Of Iron Deficiency In Chronic Kidney Disease

  11/12/2013

• Shield Therapeutics to Attend Biotechnology Industry Organization (BIO)-Europe® 2013

  10/23/2013